The purpose of Idorsia is to discover, develop and bring more, innovative medicines to patients. We have more ideas, we see more opportunities and we want to help more patients.

Products, services, technology

We have four phase 3 products: daridorexant (insomnia), clazosentan (treatment of vasospasm following a sub-arachnoid subarachnoid hemorrhage), aprocitentan (difficult to treat hypertension) and lucerastat (Fabry's disease). Our pipeline has 12 assets in total. Link

Location

Hegenheimermattweg 91, 4123 Allschwil, Switzerland

Facts & figures
  • Type of organization

    Public company

  • Year of foundation

    2017

  • Number of employees in Switzerland

    >250

Key business